Flying The Web For News.
  • 2024 Presidential Election
    2024 Presidential Election
  • Career Exam Study
    Career Exam Study
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

Details
Category: Globe NewsWire News Distribution Service

INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the presentation of clinical data at The Liver Meeting® 2024…


Posted: 2024-11-18 23:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | pliant | therapeutics | presents


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - Newscast

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

Mon, 18 Nov 2024 15:19:00 GMT INTEGRIS-PSC featured in an oral late breaker presentationSOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...

Pliant Therapeutics to Participate in the Stifel Healthcare Conference

Wed, 06 Nov 2024 05:19:00 GMT SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer ...

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Tue, 22 Oct 2024 21:30:00 GMT 1,2 "These novel highly selective MC4R agonists, which potentially eliminate adverse effects such as skin pigmentation, represents a meaningful step forward in MC4R based therapeutics for a ...





Blow Us A Whistle